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Background: Central nervous system tuberculosis is the most
severe form of extra-pulmonary tuberculosis, characterized by the
formation of rich foci, a brain form of granulomas and tuberculous
meningitis. Granulomas contain mycobacteria by recruitment of
immune cells that surround the bacteria. the cytokine tumornecro-
sis factor (TNF) has been found to be involved in the recruitment
of the immune cells and the structure maintenance of granulomas.
During central nervous system tuberculosis, excess of TNF has been
implicated in persisting hyperinﬂammation, however deﬁciency
of TNF leads to uncontrolled bacterial growth; both phenomena
causing necrotic lysis. The aim of this study was to investigate the
contribution of TNF by speciﬁc immune cell types in the control of
cerebral Mtb infection.
Methods & Materials: We investigated the role of TNF derived
frommicroglia/macrophages, neutrophils, CD4+ and CD8+ T cells in
host immunity against Mtb; using an experimental murine model
with cell type-speciﬁc gene targeting.
Results: We found that mice deﬁcient for TNF in
microglia/macrophages and neutrophils are not susceptible
to Mtb infection, with a phenotype similar to wild type mice.
Surprisingly, mice with ablation of TNF in microglia/macrophages,
neutrophils, CD4+ and CD8+ T cells were highly susceptible to
cerebralMtb infectionwith a phenotype similar to that of complete
deﬁcient TNF mice, which succumbed by 21 days post-infection.
Conclusion: Our data suggest that microglia/macrophages and
neutrophils derived TNF are not required for effective cerebral
immune response. These ﬁndings also add knowledge in develop-
ment of immunomodulatory therapy strategies of central nervous
system tuberculosis.
http://dx.doi.org/10.1016/j.ijid.2014.03.419
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Efﬁcacy of early treatment of acute hepatitis C
infection with pegylated interferon
N. Amina
Rakai Health Science, Masaka, Uganda
Background: Treatment of acute hepatitis C (HCV) in HIV-
infected patients has been poorly addressed.
Objective: To evaluate the efﬁcacy and tolerability of a 24 week
course of pegylated interferon alfa 2a (PeglFNa2a) and ribavirin for
the treatment of acute HCV infection in HIV-infected patients.
Methods & Materials: This was a prospective pilot study of 25
consecutive HIV-infected men with acute HCV infection deﬁned
by documented HCV seroconversion to anti-HCV positive anti-
body and positive qualitative HCV RNA measurement. Patients
with delectable HCV RNA (>50IU/ml) 12 weeks after diagnosis
were offered treatment with PeglFNa2a (ISO jjigAveek) and ribavi-
rin (800mg/day) for24 weeks. Sustained virolog-ical response was
deﬁned by a negative qualitative HCV RNA measurement 24 weeks
after the end of treatment.
Results: At baseline, 23patientswere takingHAART, 23patients
had HIV RNA<200 copies/ml and a median CD4 count of 345
cells/|J. Only one patient, with genotype 3 HCV, had a spontaneous
clearance of HCV RNA. Of the remaining 24 patients, four refused
anti-HCV therapy, ribavirinwas contraindicated in one and19 initi-
ated anti-HCV therapy. Median time between acute HCV diagnosis
and initiation of study treatment was 14 weeks. Of the 14 patients
who have achieved the post-treatment follow-up at 24 weeks, 10
had a sustained virological response (71%). Study treatment was
well tolerated, with no change in CD4 cell count.
Conclusion: Early treatment of acute HCV infection with
PeglFNa2a and ribavirin for 24 weeks yields a high sustained viro-
logical response rate in HIV-infected patients.
http://dx.doi.org/10.1016/j.ijid.2014.03.420
